Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Change in Account Payables of $8.8 million for Q1 2026, up 125.27% year-over-year from $3.9 million in Q1 2025, and up 691.82% quarter-over-quarter from -$1.5 million in Q4 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Change in Account Payables for 8 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 125.27% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $2.9 million (down 17.03% YoY), while the FY2025 annual figure was -$2.0 million, down 543.0% from the prior year.
- Change in Account Payables improved to $8.8 million in Q1 2026 per KYMR's latest filing, from -$1.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $8.8 million in Q1 2026 and bottomed at -$4.1 million in Q2 2025.
- Historically, Change in Account Payables has averaged $519647.1 across 5 years, with a median of $31000.0 in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 5122.67% in 2025 and fell as far as 13432.26% in 2025.
- Kymera Therapeutics' Change in Account Payables stood at -$2.1 million in 2022, then surged by 174.03% to $1.5 million in 2023, then sank by 132.98% to -$505000.0 in 2024, then slumped by 195.25% to -$1.5 million in 2025, then soared by 691.82% to $8.8 million in 2026.
- Business Quant data shows KYMR's Change in Account Payables at $8.8 million in Q1 2026, -$1.5 million in Q4 2025, and -$267000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | -3.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.94 Mn |
| Mar 31, 2026 | 8.82 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Sep 30, 2025 | -267,000.00 |
| Jun 30, 2025 | -4.13 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | -505,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 31,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | -2.73 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | -2.07 Mn |
| Sep 30, 2022 | 4.17 Mn |
| Jun 30, 2022 | -410,000.00 |
| Mar 31, 2022 | -1.44 Mn |
| Dec 31, 2021 | -1.03 Mn |
| Sep 30, 2021 | -2.92 Mn |